WEBULL
WebtradeDownload

Amgen (AMGN) Stock Looks Cheap Against Its Cash Flow Outlook

Simply Wall St · 2d ago

Amgen has ridden a powerful run in recent years, and with fresh drug data in the headlines, the real question for anyone looking at the stock is how well its current price lines up with the cash it can generate over time.

  • Over the past 5 years, Amgen has delivered a 147.9% return, which puts real pressure on the cash flow story to justify how far the share price has come.
  • Positive Phase III results for Tezspire in eosinophilic esophagitis may support expectations for future revenue and operating cash flows as the treatment moves deeper into its target market.
  • What if you looked at Amgen through its earnings instead? See what Amgen's 27.1x P/E says about the price.

For investors, the debate is whether Amgen's current share price is adequately supported by the cash flows implied by its intrinsic value estimate using a Discounted Cash Flow (DCF) approach.

If you want more context around Amgen's cash flow story, compare it with other businesses screened for 33 high quality undervalued stocks.

Is Amgen Still Cheap on Cash Flow?

The Discounted Cash Flow (DCF) approach here looks at the cash Amgen can return to shareholders over time and discounts it back to today. In this model, the business is treated as a mature but still expanding cash generator, with latest twelve month free cash flow of roughly $10.8b and projected free cash flows rising further by 2030. That mix of current scale and assumed growth is used to estimate an intrinsic value that the model suggests is substantially above the current share price of $438.34.

Because the Phase III Tezspire results point to another potential long term revenue pillar, the market reaction so far helps frame the gap between Amgen's current price and the cash flows used in the DCF. Despite that positive catalyst already in view, the stock is still priced below what these projected cash flows support. This is where the full intrinsic value estimate becomes useful context for your own work. Find out what Amgen could be worth using our Discounted Cash Flow (DCF) estimate.

The Amgen Narrative: What Would Justify Today's Price?

Simply Wall St Narratives take that DCF puzzle for Amgen and turn it into clear, competing storylines about what would need to happen to growth, margins and earnings for the share price to look materially higher or lower than it does today, all housed on the Community page. Each narrative links a single fair value estimate to a specific mix of potential catalysts and key risks, which helps you track over time which version of Amgen's future appears to be unfolding.

Community views on Amgen split between those who see expanding franchises and AI tools lifting the ceiling and those who think obesity hype masks pressure elsewhere.

Bull case: 12% undervalued

"The late stage pipeline that analysts already model, including MariTide, olpasiran and xaluritamig, is now being paired with a frontier AI laboratory and company wide agentic workflows..."

Discover why this Narrative puts Amgen at 12% undervalued.

Bear case: 22% overvalued

"MariTide's commercial ramp-up will take years post-launch, while Amgen’s high-margin legacy moats (Prolia and Enbrel) are already eroding at a brutal 30%+ YoY clip right now..."

Explore why this Narrative puts Amgen at 22% overvalued.

One more piece of the Amgen puzzle that investors should not skip

Before you get too comfortable with any fair value estimate for Amgen, it is worth knowing that our broader checks have raised specific concerns that deserve a closer look on their own. Take a closer look at 1 warning sign before settling on a valuation.